American journal of cardiovascular drugs : drugs, devices, and other interventions

Combined Treatment with GLP-1 Receptor Agonists and SGLT2 Inhibitors in Patients with Heart Failure: Review and Analysis of Observational Studies

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

A combination of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Sodium-Glucose co-transporter-2 Inhibitor (SGLT2i) may provide complementary benefits in heart failure patients.

  • Combination therapy could enhance treatment outcomes compared to SGLT2i alone.
  • Both therapies are administered alongside standard heart failure care.
  • The analysis focuses on patients who have existing heart failure at baseline.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Christopher Daniel Tristan, Irnizarifka Irnizarifka, Erlangga Masykur Kynaya, Mellisa Gani, Matthew Aldo Wijayanto, An Aldia Asrial, and Raymond Pranata declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.
PubMed

Related papers

Oct '25
Heart and kidney results of combining two diabetes drugs: GLP-1 receptor agonists and SGLT2 inhibitors
top 2% journal
cited by 5 papers
systematic review
Oct '21
Comparing diabetes drugs for people with heart disease: a network analysis of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors
cited by 44 papers
systematic review
Oct '25
How safe and effective combining two diabetes drugs (SGLT2 inhibitors and GLP-1 receptor agonists) is for people with type 2 diabetes
top 2% journal
cited by 12 papers
systematic review
Apr '26
Heart-related outcomes in diabetic patients treated with SGLT2 inhibitors and GLP-1 receptor agonists
top 50% journal
systematic review
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
Jun '20
Combining two diabetes medicines that affect blood sugar control: a review and analysis
cited by 81 papers
systematic review
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Nov '25
Preventing heart problems in heart failure with mildly reduced or normal heart pumping: a detailed analysis of eight clinical trials using individual patient data
top 2% journal
journal article
Jul '23
SGLT2 inhibitor and GLP-1 receptor agonist treatments and kidney and blood vessel outcomes in type 1 diabetes: a real-world study
top 2% journal
cited by 85 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief